OCU400 is Ocugen’s novel modifier gene therapy for retinitis pigmentosa (RP). The OCU400 (AAV5-h NR2E3) gene therapy platform ...

Boyer discusses a potential treatment for diabetic retinopathy and macular degeneration using suprachoroidal injections, ...

Kiora Pharmaceuticals has granted Senju Pharmaceutical an exclusive option to exercise rights to an exclusive development and ...

VG801 is a dual AAV gene therapy that leverages mRNA trans-splicing via the vgRNA REVeRT and vgAAV platforms to deliver the ...

IVMED-85 is a preservative-free, non-atropine daily drop that slows myopia progression by strengthening scleral and corneal ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Weighing the benefits and trade-offs of preserved versus preservative-free glaucoma treatments is key to optimizing long-term ...

Retinal vascular change or degeneration already has been associated with Alzheimer and Parkinson disease, and the findings ...

SpyGlass Pharma secures $75 million in Series D funding to enhance its innovative drug delivery platform for long-term ...

Prevent Blindness offers resources for Cataract Month, empowering patients and caregivers with knowledge on cataracts and ...

A recent US Court of International Trade decision was made on May 28 to permanently prohibit all tariffs imposed by President ...

The phase 3 trial observed the treatment of chronic night driving impairment in keratorefractive patients with reduced ...